Company profile
Eloxx Pharmaceuticals, Inc.
NASDAQ:ELOXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EXALUREN | phase2 | — | 8 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04069260 | phase2 | terminated | 2019-08-02 | 2019-12-17 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis |
| NCT04126473 | phase2 | completed | 2019-11-05 | 2022-04-06 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele |
| NCT04135495 | phase2 | completed | 2019-11-25 | 2022-10-03 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele |
| NCT05448755 | phase2 | completed | 2022-11-28 | 2023-09-11 | Eloxx Pharmaceuticals, Inc. | A Study of ELX-02 in Patients With Alport Syndrome |
| NCT03776539 | phase1 | completed | 2019-01-04 | 2019-07-30 | Eloxx Pharmaceuticals, Inc. | A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02 |
FDA applications (0)
No records yet.